GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyfuse Biomedical KK (TSE:4892) » Definitions » Debt-to-Asset

Cyfuse Biomedical KK (TSE:4892) Debt-to-Asset : 0.21 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cyfuse Biomedical KK Debt-to-Asset?

Cyfuse Biomedical KK's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was 円468.00 Mil. Cyfuse Biomedical KK's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was 円336.00 Mil. Cyfuse Biomedical KK's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was 円3,844.75 Mil. Cyfuse Biomedical KK's debt to asset for the quarter that ended in Jun. 2024 was 0.21.


Cyfuse Biomedical KK Debt-to-Asset Historical Data

The historical data trend for Cyfuse Biomedical KK's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyfuse Biomedical KK Debt-to-Asset Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
0.24 0.22 0.19 0.22

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.20 0.20 0.22 0.21 0.21

Competitive Comparison of Cyfuse Biomedical KK's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyfuse Biomedical KK's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cyfuse Biomedical KK's Debt-to-Asset falls into.



Cyfuse Biomedical KK Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cyfuse Biomedical KK's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Cyfuse Biomedical KK's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyfuse Biomedical KK  (TSE:4892) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Cyfuse Biomedical KK Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cyfuse Biomedical KK's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyfuse Biomedical KK Business Description

Traded in Other Exchanges
N/A
Address
3-5-27, Mita, West Wing-1st Floor. Sumitomo Fudosan Mita Twin Building, Minato-ku, Tokyo, JPN
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine related products.

Cyfuse Biomedical KK Headlines

No Headlines